Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells
Aim. To study efficacy of htuximab in patients with resistant B-cell lymphoma on high-dose chemotherapy. Material and methods. From September 2000 to April 2002 we studied efficacy and tolerance of rituximab at different stages of high-dose chemotherapy. The treatment was given to 10 patients with h...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2003-01-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/29296 |
id |
doaj-b52d189914304434bab85b3da9b4bdab |
---|---|
record_format |
Article |
spelling |
doaj-b52d189914304434bab85b3da9b4bdab2020-11-25T03:23:04Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422003-01-01781656826332Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cellsV V PtushkinK L ChimishkyanN V ZhukovD Sh OsmanovL Yu AndreevaN N TupitsynV В LarionovaD M MkheidzeI V PoddubnayaAim. To study efficacy of htuximab in patients with resistant B-cell lymphoma on high-dose chemotherapy. Material and methods. From September 2000 to April 2002 we studied efficacy and tolerance of rituximab at different stages of high-dose chemotherapy. The treatment was given to 10 patients with histologically verified CD20+ non-Hodgkln's lymphoma: diffuse large-cell (n = 4), Berkitfs (n = 2), follicular (n - 3), mantle-cell (n = 1). Five patients with diffuse large-cell lymphoma and Berkitt's lymphoma had a primary resistant course of the disease, one patient with diffuse large-cell lymphoma had a refractory recurrence. Follicular and mantle-cell lymphomas were characterized by a resistant course and large tumar masses. The patients received 1-2 courses of induction chemotherapy with dexa-BEAM with collection of peripheral stem cells followed by high-dose chemotherapy (BEAM-9, CBV+mitoxantron-1) with transplantation of autologous stem blood cells. Rituximab infusion (375 mg/m2) was conducted before the collection of the stem cells, prior to high-dose chemotherapy and in posttransplantation period after recovery of hemopoiesis. Results. 4 patients achieved complete remission, 3 - partial remission, 2 had progression and 1 - stabilization. In mean follow-up 11 (2-20) months 7 of 10 patients were alive, overall survival being 15 + 2.4 months (95% confidence interval 10-19.7), median was not reached. 5patients are in complete remission: 2 of them without further treatment, 3 - after progression and repeat therapy including rituximab and interferon-a or rotuximab and CHOP chemotherapy. Conclusion. The addition of rituximab can improve the results of high-dose chemotherapy of patients with non-Hodgkin's lymphoma resistant to standard doses of cytostatics. Repeat use of this drug can be effective in some patients with progression after high-dose chemotherapy with rituximab.https://ter-arkhiv.ru/0040-3660/article/view/29296non-hodgkin 's lymphomashigh-dose chemotherapyautologous transplantation of stem cellsrituximab |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
V V Ptushkin K L Chimishkyan N V Zhukov D Sh Osmanov L Yu Andreeva N N Tupitsyn V В Larionova D M Mkheidze I V Poddubnaya |
spellingShingle |
V V Ptushkin K L Chimishkyan N V Zhukov D Sh Osmanov L Yu Andreeva N N Tupitsyn V В Larionova D M Mkheidze I V Poddubnaya Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells Терапевтический архив non-hodgkin 's lymphomas high-dose chemotherapy autologous transplantation of stem cells rituximab |
author_facet |
V V Ptushkin K L Chimishkyan N V Zhukov D Sh Osmanov L Yu Andreeva N N Tupitsyn V В Larionova D M Mkheidze I V Poddubnaya |
author_sort |
V V Ptushkin |
title |
Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
title_short |
Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
title_full |
Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
title_fullStr |
Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
title_full_unstemmed |
Mabtera (rituximab) treatment of patients with refractory' course of B-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
title_sort |
mabtera (rituximab) treatment of patients with refractory' course of b-cell lymphoma on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2003-01-01 |
description |
Aim. To study efficacy of htuximab in patients with resistant B-cell lymphoma on high-dose chemotherapy.
Material and methods. From September 2000 to April 2002 we studied efficacy and tolerance of rituximab at different stages of high-dose chemotherapy. The treatment was given to 10 patients with histologically verified CD20+ non-Hodgkln's lymphoma: diffuse large-cell (n = 4), Berkitfs (n = 2), follicular (n - 3), mantle-cell (n = 1). Five patients with diffuse large-cell lymphoma and Berkitt's lymphoma had a primary resistant course of the disease, one patient with diffuse large-cell lymphoma had a refractory recurrence. Follicular and mantle-cell lymphomas were characterized by a resistant course and large tumar masses. The patients received 1-2 courses of induction chemotherapy with dexa-BEAM with collection of peripheral stem cells followed by high-dose chemotherapy (BEAM-9, CBV+mitoxantron-1) with transplantation of autologous stem blood cells. Rituximab infusion (375 mg/m2) was conducted before the collection of the stem cells, prior to high-dose chemotherapy and in posttransplantation period after recovery of hemopoiesis.
Results. 4 patients achieved complete remission, 3 - partial remission, 2 had progression and 1 - stabilization. In mean follow-up 11 (2-20) months 7 of 10 patients were alive, overall survival being 15 + 2.4 months (95% confidence interval 10-19.7), median was not reached. 5patients are in complete remission: 2 of them without further treatment, 3 - after progression and repeat therapy including rituximab and interferon-a or rotuximab and CHOP chemotherapy.
Conclusion. The addition of rituximab can improve the results of high-dose chemotherapy of patients with non-Hodgkin's lymphoma resistant to standard doses of cytostatics. Repeat use of this drug can be effective in some patients with progression after high-dose chemotherapy with rituximab. |
topic |
non-hodgkin 's lymphomas high-dose chemotherapy autologous transplantation of stem cells rituximab |
url |
https://ter-arkhiv.ru/0040-3660/article/view/29296 |
work_keys_str_mv |
AT vvptushkin mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT klchimishkyan mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT nvzhukov mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT dshosmanov mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT lyuandreeva mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT nntupitsyn mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT vvlarionova mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT dmmkheidze mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells AT ivpoddubnaya mabterarituximabtreatmentofpatientswithrefractorycourseofbcelllymphomaonhighdosechemotherapywithautologoustransplantationofhemopoiesisprecursorcells |
_version_ |
1724608000147062784 |